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Germline intragenic mutations in PTEN are associated with 80% of patients with Cowden syndrome (CS) and
60% of patients with Bannayan-Riley-Ruvalcaba syndrome (BRRS). The underlying genetic causes remain to be
determined in a considerable proportion of classic CS and BRRS without a polymerase chain reaction (PCR)-
detectable PTEN mutation. We hypothesized that gross gene deletions and mutations in the PTEN promoter might
alternatively account for a subset of apparently mutation-negative patients with CS and BRRS. Using real time
and multiplex PCR techniques, we identified three germline hemizygous PTEN deletions in 122 apparently mutation-
negative patients with classic CS (Np95) or BRRS (Np27). Fine mapping suggested that one deletion encompassed
the whole gene and the other two included exon 1 and encompassed exons 1–5 of PTEN, respectively. Two patients
with the deletion were diagnosed with BRRS, and one patient with the deletion was diagnosed with BRRS/CS
overlap (features of both). Thus 3 (11%) of 27 patients with BRRS or BRRS/CS-overlap had PTEN deletions.
Analysis of the PTEN promoter revealed nine cases (7.4%) harboring heterozygous germline mutations. All nine
had classic CS, representing almost 10% of all subjects with CS. Eight had breast cancers and/or benign breast
tumors but, otherwise, oligo-organ involvement. PTEN protein analysis, from one deletion-positive and five PTEN-
promoter-mutation–positive samples, revealed a 50% reduction in protein and multiple bands of immunoreactive
protein, respectively. In contrast, control samples showed only the expected band. Further, an elevated level of
phosphorylated Akt was detected in the five promoter-mutation–positive samples, compared with controls, indicating
an absence of or marked reduction in functional PTEN. These data suggest that patients with BRRS and CS without
PCR-detected intragenic PTEN mutations be offered clinical deletion analysis and promoter-mutation analysis,
respectively.
Cowden syndrome (CS [MIM 158350]) is an autosomal
dominant disorder characterized by multiple hamartomas
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affecting derivatives of all three germ layers and by an
increased risk of breast, thyroid, and endometrial neo-
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Figure 1 Real-time quantitative multiplex PCR results for 12 normal control subjects and 122 apparently mutation-negative individuals
with CS and/or BRRS at PTEN exon 1. Normal control subjects showed 2(DDCT) values between 0.93 and 1.21. Patients with two copies of
PTEN displayed values between 0.81 and 1.35, whereas patients with hemizygous deletions (one copy) had values between 0.45 and 0.60.
plasia (Eng 2000). PTEN/MMAC1/TEP1 (MIM 601728)
is a tumor-suppressor gene located at 10q23.3, which
antagonizes the phosphoinositol-3-kinase (PI3K)/Akt
pathway (reviewed by Waite and Eng [2002]). Proper
PTEN signaling leads to G1 cell–cycle arrest and/or ap-
optosis (reviewed by Waite and Eng [2002]). When as-
certained strictly by International Cowden Consortium
Operational Diagnostic Criteria, ∼80% of patients with
CS demonstrate germline PTEN mutations (Liaw et al.
1997; Marsh et al. 1998). In addition, ∼60% of individu-
als with Bannayan-Riley-Ruvalcaba syndrome (BRRS
[MIM 153480])—another autosomal dominant hamar-
toma syndrome characterized by a classic triad of mac-
rocephaly, lipomatosis, and speckled penis—carry germ-
line PTEN mutations (Marsh et al. 1997, 1998, 1999).
Subsequently, the clinical spectrum of disorders associ-
ated with germline PTEN mutations has expanded to
include seemingly disparate syndromes, such as Proteus
syndrome (MIM 176920), Proteus-like syndromes, and
VATER association with macrocephaly (Zhou et al.
2000b, 2001; Reardon et al. 2001; Smith et al. 2002).
The underlying genetic causes remain undetermined in
20% and 40%, respectively, of individuals with classic
CS and BRRS in whom no mutations have been detected
by conventional mutation-detection techniques (re-
viewed by Waite and Eng [2002]). Because CS is believed
to be without genetic heterogeneity (Nelen et al. 1996),
we hypothesized that apparently PTEN-mutation–nega-
tive CS and BRRS may be attributed to large gene re-
arrangements and deletions, which cannot be detected
by conventional techniques, and promoter mutations. To
test our hypotheses, therefore, we used a combination
of real-time quantitative multiplex PCR analysis, fluo-
rescent-based semiquantitative PCR assay, and micro-
satellite analysis to define and characterize PTEN and
regional deletions in a large series of probands with CS
and BRRS previously found not to have intragenic
PTEN mutations. Further, deletion-negative samples
were subjected to sequence analysis of the promoter re-
gion of PTEN. Finally, we biochemically characterized
the potential pathogenicity of the deletion and promoter
mutations.
After written informed consent was received, DNA
from peripheral blood was obtained from 122 unrelated
individuals diagnosed with CS ( ; 79%), accord-Np 95
ing to the International Cowden Consortium diagnostic
criteria (Eng 2000), or BRRS ( ; 21%), by clinicalNp 27
definition (Gorlin et al. 1992). Real-time quantitativePCR
analysis was performed by use of the ABI 7700 Sequence
Detector System (ABI/Perkin Elmer), as described else-
where (Sieber et al. 2002). PTEN exons 1 and 5 were
chosen as targets for the real-time quantitative PCR as-
say, whereas the remaining exons were analyzed by use
of fluorescent-based semiquantitative multiplex PCR as-
say. Human RET exon 8 was chosen as the internal
control. Primer and probe sequences are listed in table 1.
The raw data obtained from real-time PCR was analyzed
by use of the comparative CT method (as described in
User Bulletin No. 2, ABI/Perkin Elmer), with normali-
zation to the internal control, RET. Samples without
406 Am. J. Hum. Genet. 73:404–411, 2003
Table 1
Probes and Primers Used for Real-Time Quantitative Multiplex PCR, Fluorescent
Semiquantitative Multiplex PCR Assay, and Promoter Sequencing
Primer/Probe
Sequence
(5′r3′)
Amplicon Size
(bp)
PTEN E1:
Forward GAGGATGGATTCGACTTAGACTTGA
Reverse CCCACGTTCTAAGAGAGTGACAGAA 85
Probe FAM-CCTGTATCCATTTCTG-MGBNF
PTEN E5:
Forward CCTACTTGTTAATTAAAAATTCAAGAGTTTTTT
Reverse GTGGGTTATGGTCTTCAAAAGGATA 98
Probe FAM-TGTGCAACTGTGGTAAA-MGBNF
RET E8:
Forward GTCCTGTGCAGTCAGCAAGAGA
Reverse CCACTCACACCTGCCTGTTG 79
Probe VIC-CCTCACACTCCAGCCG-MGBNF
PTEN E2:
Forward FAM-GTTTGATTGCTGCATATTTCAG
163
Reverse TGAAATAGAAAATCAAAGCATTC
PTEN E3:
Forward FAM- AAAATCTGTCTTTTGGTTTTTC
178
Reverse TTGCAAGCATACAAATAAGAA
PTEN E4:
Forward FAM-CATTATAAAGATTCAGGCAAT
205
Reverse GACAGTAAGATACAGTCTATC
PTEN E5:
Forward FAM-CTTTTTACCACAGTTGCACA
282
Reverse GGAAAGGAAAAACATCAAAA
PTEN E6:
Forward FAM-CCTGTTAAAGAATCATCTGGA
120
Reverse AAGGATGAGAATTTCAAGCA
PTEN E7:
Forward FAM- AGGCATTTCCTGTGAAATAA
172
Reverse TTGATATCACCACACACAGG
PTEN E8:
Forward FAM-CTCAGATTGCCTTATAATAGTC
245
Reverse TCTGAGGTTTCCTCTGGTC
PTEN E9:
Forward FAM-TCATATTTGTGGGTTTTCATT
260
Reverse TCATGGTGTTTTATCCCTCT
RET E8:
Forward FAM-CTGTGACCCTGCTTGTCT
135
Reverse CACTCACACCTGCCTGTT
Promoter:
Forward GCGTGGTCACCTGGTCCTTT
683
Reverse GCTGCTCACAGGCGCTGA
PTEN deletions were expected to yield 2(DDCT) values
close to 1, whereas samples with hemizygous deletion
or duplication were expected to give 2(DDCT) values close
to 0.5 or 1.5, respectively. Positive results were con-
trolled on at least three independent experiments. We
found three (2.5%) individuals who harbored hemizygous
germline deletions encompassing all or part of PTEN.
The 2(DDCT) values ranged 0.45–0.60, for the three pa-
tients with deletions; 0.81–1.35, for the deletion-nega-
tive cases; and 0.93–1.21, for the 12 normal individuals
tested (fig. 1). One sample (1397-1) showed deletion of
all nine PTEN exons, which suggests that the deletion
encompassed the entire gene. The other two samples
(141-2 and 1621-1) had deletions encompassing exons
1–5 and exon 1 only, respectively. No sample was found
to have exonic duplication. Further, we included a frag-
ment of PTEN exon 5 in the fluorescent multiplex PCR
assay and found no deletions except for the ones detected
by real-time quantitative multiplex PCR, thereby confirm-
ing the sensitivity of fluorescent semiquantitative multi-
plex PCR assay.
To assess the extent of the PTEN germline deletions,
three polymorphic markers intragenic to PTEN and five
polymorphic markers flanking the 10q23.3 region were
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Figure 2 Genotyping results for the three patients with BRRS
and/or CS with hemizygous PTEN deletions.
Figure 3 Germline PTEN promoter mutations and polymorphisms found in probands with CS
genotyped as described elsewhere (Marsh et al. 1999;
Zhou et al. 2000a) (fig. 2). Markers AFMa086wg9,
IVS4109 ins/del TCTTA (IVS4109), and IVS832
G/T (IVS832) are intragenic to PTEN, whereas
D10S215, D10S1765, and D10S541 are500 Kb up- or
downstream of PTEN. Markers D10S532 and D10S583
are located ∼3 cM upstream and 5 cM downstream of
PTEN, respectively. All three patients with deletions
were apparently homozygous (which suggests hemi-
zygosity) at markers closest to or within the PTEN gene
(D10S1765, AFMa086wg9, IVS4109, and IVS832),
consistent with the hemizygous deletions already iden-
tified by real-time quantitative multiplex PCR and fluo-
rescent multiplex PCR assays. In one case (1397-1),
“homozygosity” spanned from the upstream marker
D10S1765 to D10S541, downstream of PTEN, con-
cordant with whole-gene deletion detected by the quan-
titative PCR assays, and suggesting the deletion which
also includes all of the PTEN promoter and likely all of
the 3′ UTR. The second deletion case (141-2) showed
“homozygosity” at D10S215, D10S1765, AFMa086wg9,
and IVS4109 and heterozygosity at IVS832, consis-
tent with partial PTEN deletion, encompassing exons
1–5. In the third case (1621-1), although the homozy-
gosity spanned from D10S215 to IVS832, deletion was
detected only at exon 1 by real-time quantitative PCR
assay, which suggests that the three intragenic markers
are truly homozygous. All these deletions likely extend
to at least 50 kb upstream of the translational start site
(D10S1765). To investigate whether these three deletions
include another gene close to the 10q23.3 region, we
analyzed MINPP1, located ∼500 kb upstream of PTEN,
using semiquantitative duplex PCR assay; no evidence
of involvement of this gene was found, thus also ex-
cluding the relevant juvenile polyposis gene BMPR1A
(upstream of MINPP1) as part of the deletion (fig. 2).
Germline DNA from the remaining 119 patients with-
out deletions was subsequently subjected to sequence
analysis for mutations in the 600-bp full-promoter region
of PTEN. Primers were designed to amplify the full pro-
moter region between1344 bp and745 bp upstream
of the translation start codon (Sheng et al. 2002) (table
1). Ten heterozygous sequence variants within the PTEN
promoter region were found in nine patients with CS
(9/119, 7.6% of total; 9/97, 10% of CS) (fig. 3). None
of these promoter sequence variants were found among
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Figure 4 Aberrant PTEN protein species and increased phos-
phorylation of Akt in promoter-mutation samples. Samples from pa-
tients with promoter mutations (P), a patient who is PTEN-mutation
negative (N), and normal control subjects (C) were analyzed. A, West-
ern analysis for PTEN protein. Open arrows indicate the expected
molecular weight of PTEN; closed arrows indicate the slower mi-
grating band. B, Western analysis for P-Akt.
186 normal white control subjects (372 chromosomes),
which suggests that the former are likely pathogenic. Two
other sequence variants (903 G/A and1026 C/A) were
present in both patients and normal control individuals
with similar allele frequencies (data not shown), which
suggests that they were indeed polymorphisms.
To functionally assess the PTEN-promoter-point mu-
tations, cellular protein from five case subjects with pro-
moter mutations was obtained during Trizol isolation of
RNA and was subjected to western blot analysis (Waite
and Eng 2003). Control samples and a sample from a
patient with CS who was negative for the PTEN mutation
display a single immunoreactive protein of the correct size
(fig. 4). It is interesting that samples from patients car-
rying the promoter mutations showed a decrease in PTEN
protein of the correct molecular weight (fig. 4A, open
arrowhead), concordant with a dramatic increase of a
slightly lower band (fig. 4A, closed arrowhead). This
lower band is visible in the PTEN-mutation–negative CS
sample and in an occasional control sample but not to
the same extent as the promoter-mutation samples and
never with a loss of the correct PTEN band. Three of the
five promoter-mutation–positive cases had a laddering ef-
fect, with several bands recognized at both lower and
higher molecular weights (fig. 4A), which has not been
observed in 32 control samples or 23 PTEN-mutation–
negative samples (data not shown). These data strongly
suggest that the lower molecular weight band and the
laddering effect are specific and related to the promoter
mutations in these patients.
We next investigated if the PTEN protein produced
in these patients was active. PTEN antagonizes the PI3K/
Akt pathway by decreasing phosphatidylinositol-3,4,5
triphosphate levels, which results in decreased Akt phos-
phorylation (reviewed by Waite and Eng [2002]). Thus,
active PTEN results in low Akt phosphorylation, and
deficient PTEN results in increased Akt phosphorylation.
Figure 4B shows that, in control and PTEN-mutation–
negative samples, the level of phosphorylated Akt (de-
tected by an antiphospho-Akt antibody) is low to unde-
tectable, which indicates active PTEN function. In con-
trast, the level of phosphorylated Akt in the samples from
cases carrying promoter mutations are dramatically ele-
vated (fig. 4B). These data indicate that the PTEN protein
produced has nonfunctional lipid phosphatase activity.
It is interesting to note that PTEN is a dual-substrate
phosphatase that dephosphorylates both lipid and pro-
tein substrates (reviewed by Waite and Eng [2002]). At
this time, we can accurately assess only the lipid phos-
phatase activity by monitoring the levels of Akt phos-
phorylation. Although our lab has shown that the protein
phosphatase activity of PTEN regulates the down regu-
lation of the mitogen-activated protein kinase pathway
(Weng et al. 2001), we have found that the level of ac-
tivation of this pathway varies considerably, even in nor-
mal controls (K. A. Waite and C. Eng, unpublished ob-
servations). Therefore, we are unable to reliably inves-
tigate changes in the protein phosphatase activity of
PTEN that may arise from various PTEN mutations. It
is interesting to postulate that various degrees of changes
in both the lipid and protein phosphatase activities may
play a role in the wide range of clinical manifestations of
CS and BRRS.
There is little doubt that all three deletions are func-
tionally deleterious, as all three likely include the pro-
moter as well as all or part of PTEN. Protein analysis on
the lymphoblastoid cell lines of one of the three deletion-
positive patients revealed ∼50% reduction in PTEN pro-
tein level, consistent with hemizygosity of PTEN (K. A.
Waite and C. Eng, unpublished data). All three patients
had a diagnosis of BRRS or BRRS/CS overlap. Two of
these probands have gastrointestinal polyposis. Although
our conclusion is based on a small sample size, there is
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Table 2
Family-as-Unit Clinical Features of Probands Positive for PTEN Promoter Mutation
Multiorgana Breast Cancer Thyroid Cancer Uterine Cancer Mutation
No No No No 1000TC, 1238ArG
No Yes No No 1110ArG
No No No No 1084CrT
No No Yes No 930GrA
No Yes No No 920GrT
No Yes No No 895ArG
Yes Yes Yes No 861GrT
No Yes Yes No 834CrT
No Yes No No 764ArG
a Multiorgan involvement operationally defined as at least five organs involved, as detailed
by Marsh et al. (1998).
a trend toward gastrointestinal hamartomatous poly-
posis in individuals with deletions, compared with the
119 patients with CS or BRRS without deletions (Pp
; Fisher’s two-tailed exact test). Although our patients’.1
deletions are not cytogenetically obvious, at least three
other unrelated patients with CS or BRRS have been
reported elsewhere to have deletions or rearrangements
in the PTEN region detected by cytogenetics (Arch et
al. 1997; Tsuchiya et al. 1998; Marsh et al. 1999; Ahmed
et al. 2000). All three with cytogenetically detected PTEN
deletion or rearrangements carried the clinical diagnosis
of BRRS. Over all, therefore, at least five probands with
BRRS have been found to have deletions of or encom-
passing PTEN. Given that hemizygous PTEN deletions
detected in probands with BRRS encompassed from sin-
gle exon to whole gene, it is very likely that certain “neat”
single-exon deletions—such as the one in patient 1621–1,
involving only exon 1—could be missed by use of FISH
technique with application of a designed probe.
Until now, the PTEN promoter had not been exam-
ined in patients with CS and/or BRRS. However, in vitro
work has shown that activated PPARg and p53 result in
up-regulated PTEN transcription (Patel et al. 2001; Stam-
bolic et al. 2001; Virolle et al. 2001), which suggests
that alterations of the promoter sequence could result
in changes to PTEN protein structure, levels, and func-
tion. Among 119 mutation-negative or deletion-negative
CS or BRRS cases, nine probands with CS were found to
carry germline heterozygous point mutations in the pro-
moter. Of significance, all nine individuals with PTEN-
promoter mutations had a diagnosis of classic CS yet
had relatively mild phenotypic features, as operationally
defined by oligo-organ involvement (involvement of fewer
than four organs; see Marsh et al. [1998] for classification)
(table 2). It is interesting that one deletion-positive pro-
band with exon 1 and upstream involvement had simi-
larly mild features, with only two-organ involvement,
macrocephaly, and lipomas. The deletion encompassing
exons 1–5 in patient 141-2 was also present in a sibling,
141–1, both of whom have features of both CS and BRRS.
It would be interesting to see whether these promoter
mutations are also present in affected relatives of familial
cases. Collection and analysis of parental DNA of these
case subjects with promoter mutations are ongoing.
Of the 10 promoter mutations (one patient had two
different sequence variants), 5 were localized to the mini-
mum PTEN promoter region (958 to821), 2 of which
(920GrT and 930GrA) are predicted to alter two
putative Sp1 transcription factor–binding sites (fig. 3).
Further, protein analysis revealed a reduced expression
of wild-type PTEN, a strong lower–molecular-weight
immunoreactive band, and a laddering effect of protein
immunoreactive with a specific monoclonal antibody
against human PTEN, which suggests that these point
nucleotide substitutions are functionally significant and,
thus, represent promoter mutations. These data suggest
that the promoter variants may result in alternative start
sites that yield PTEN protein of various sizes (fig. 4A).
It is interesting to note that the two samples with
mutations at the two putative Sp1 binding sites were the
two with doublet PTEN-immunoreactive bands but no
laddering effect (fig. 4A). Although the transcriptional
regulation of PTEN is only now beginning to be eluci-
dated, we suspect that these variants would alter PTEN
transcription, which would result in impaired protein
expression. The presence of some wild-type protein, to-
gether with PTEN proteins of various sizes, might be
postulated to result in the milder phenotype associated
with these promoter variants. It is also possible that such
mutations result in posttranslational modifications, which
could result in altered mobility during SDS-PAGE. An-
other possibility is that the PTEN protein formed is al-
tered at the protein level, which results in targeted deg-
radation, and it is the degradation of PTEN protein that
we are observing. The mechanisms of PTEN degradation
are only now being understood (Vazquez et al. 2000;
Torres and Pulido 2001; Waite and Eng 2003). Improper
PTEN degradation could also result in impaired protein
expression. Further analysis, as patient sample material
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becomes available, will be necessary to determine the
exact mechanism of the laddering effect.
Regardless of the mechanism of lower molecular weight
proteins, we have demonstrated that the PTEN protein
species produced in these promoter-mutation–positive pa-
tients is deficient. The levels of phosphorylated-Akt were
significantly higher in samples haboring promoter se-
quence variants, compared with control subjects and
PTEN-mutation–negative samples (fig. 4B), which in-
dicates an increase in the activity of the pro-proliferative
PI3K/Akt pathway.
On the basis of our observations that 11% of individ-
uals with features of BRRS were found to have a deletion,
it may be prudent to offer deletion analysis to patients
with BRRS and patients with CS/BRRS with gastrointes-
tinal polyposis but without PCR-based intragenic PTEN
mutations. Further, our ∼10% promoter-mutation fre-
quency among probands with CS previously found to
be PCR-mutation negative and deletion negative does
suggest that promoter analysis might be useful in the
clinical setting. That these promoter variants are dele-
terious and likely causative of CS has been demonstrated
by aberrant PTEN protein bands on western blot, which
resulted in activation of the pro-proliferative Akt path-
way. Indeed, western analyses should be considered a use-
ful molecular diagnostic adjunct to determine function-
ality of promoter variants.
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